23511-05-9Relevant academic research and scientific papers
Electron Impact Mass Spectrometry of 3-Cyclohexen-1-ol and Related Compounds
Braem, Daniel,Siles, Samuel,Guelacar Fazil O.,Buchs, Armand
, p. 102 - 106 (1982)
The electron impact mass spectrum of 3-cyclohexen-1-ol has been studied, especially with regard to retro Diels-Alder reaction.Six deuterium labelled analogues and two dimethyl substituted homologues were synthesised.Contrary to what we have observed with 2-cyclohexen-1-ol, the double bond migration which precedes the retro Diels-Alder reaction plays a minor role.
COMPOUND SERVING AS IRAK INHIBITOR
-
Paragraph 0296; 0302; 0329-0330, (2021/10/07)
The present disclosure relates a compound as an IRAK inhibitor. Specifically, the present disclosure provides a compound of formula I, or a cis-trans isomer, an optical isomer, a racemate, a pharmaceutically acceptable salt, a prodrug, a deuterated derivative thereof, a hydrate or a solvate thereof. The compounds disclosed herein have potent inhibitory effects on IRAK and thus have therapeutic effect on IRAK-related diseases.
Stereospecific Nickel-Catalyzed Reductive Cross-Coupling of Alkyl Tosylate and Allyl Alcohol Electrophiles
Alexanian, Erik J.,Tercenio, Quentin D.
supporting information, p. 7215 - 7219 (2021/09/22)
The stereospecific cross-coupling of easily accessed electrophiles holds significant promise in the construction of C-C bonds. Herein, we report a nickel-catalyzed reductive coupling of allyl alcohols with chiral, nonracemic alkyl tosylates. This cross-coupling delivers valuable allylation products with high levels of stereospecificity across a range of substrates. The catalytic system consists of a simple nickel salt in conjunction with a commercially available reductant and importantly represents a rare example of a cross-coupling involving the C-O bonds of two electrophiles.
AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF
-
Page/Page column 141-142, (2021/02/26)
Disclosed herein is an aminopyrazine compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.
AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR
-
Paragraph 0155, (2021/05/29)
A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.
ROR[gamma] inhibitors, preparation method thereof and application of the ROR[gamma] inhibitors in medicine
-
Paragraph 0275-0276; 0280-0282, (2021/05/26)
The present specification provides compounds of formula (I) shown in the specification: or a pharmaceutically acceptable salt thereof, a deuterated compound, a tautomer, a cis-trans-isomer, a mesomer, a raceme, an enantiomer, a diastereoisomer, or a mixtu
TARGETED BIFUNCTIONAL DEGRADERS
-
Page/Page column 174, (2021/04/17)
The present invention provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present invention provides bifunctional compounds that can be used to promote or enhance degradation of certain autoantibodies. In certain embodiments, treatment or management of a disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein or the autoantibody in the subject. Thus, in certain embodiments, administration of a compound of the invention to the subject removes or reduces the circulation concentration of the circulating protein or the autoantibody, thus treating, ameliorating, or preventing the disease and/or disorder. In certain embodiments, the circulating protein is TNF.
SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS
-
Page/Page column 52-53, (2020/06/10)
Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein X is CR1 or N; and G, A, R1, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
Potent and selective inhibitors of receptor-interacting protein kinase 1 that lack an aromatic back pocket group
Hamilton, Gregory L.,Chen, Huifen,Deshmukh, Gauri,Eigenbrot, Charles,Fong, Rina,Johnson, Adam,Kohli, Pawan Bir,Lupardus, Patrick J.,Liederer, Bianca M.,Ramaswamy, Sreemathy,Wang, Haowei,Wang, Jian,Xu, Zhaowu,Zhu, Yunliang,Vucic, Domagoj,Patel, Snahel
supporting information, p. 1497 - 1501 (2019/04/17)
Receptor-interacting protein kinase 1 (RIPK1), a key component of the cellular necroptosis pathway, has gained recognition as an important therapeutic target. Pharmacologic inhibition or genetic inactivation of RIPK1 has shown promise in animal models of disease ranging from acute ischemic conditions, chronic inflammation, and neurodegeneration. We present here a class of RIPK1 inhibitors that is distinguished by a lack of a lipophilic aromatic group present in most literature inhibitors that typically occupies a hydrophobic back pocket of the protein active site. Despite not having this ubiquitous feature of many known RIPK1 inhibitors, we were able to obtain compounds with good potency, kinase selectivity, and pharmacokinetic properties in rats. The use of the lipophilic yet metabolically stable pentafluoroethyl group was critical to balancing the potency and properties of optimized analogs.
BROMODOMAIN INHIBITORS
-
Paragraph 00609, (2018/04/27)
Provided herein are compounds of formula (I) wherein R 1, Y, L 1, G 1, X 1, X 2, L 2, R 2, R 3, and R 4 have any of the values defined in the specification,
